RWJ-51204 |
|
Catalog No.GC31049
|
RWJ-51204 est un agoniste partiel du récepteur GABA(A), avec un Ki de 0,2-2 nM au site des benzodiazépines sur les récepteurs GABA(A).
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 205701-85-5
Sample solution is provided at 25 µL, 10mM.
RWJ-51204 is a partial agonist of GABA(A) receptor, with Ki of 0.2-2 nM to the benzodiazepine site on GABA(A) receptors.
RWJ-51204 binds to receptors in the cerebral cortex, cerebellum, or medulla-spinal cord with Ki ranging from 0.2 to 0.6 nM.
RWJ-51204 is orally active in anxiolytic efficacy tests. WJ 51204 dose-relatedly antagonizes PTZ-induced clonic convulsions when administered orally (ED50 = 0.04 mg/kg). RWJ-51204 is effective in the conflict test in monkeys (ED50 of approximately 0.5 mg/kg p.o.). RWJ-51204 potently impairs rotarod performance in rats (ED50 = 0.12 mg/kg), and all rats given RWJ-51204 orally at 30 mg/kg exhibit sedation, reduced skeletal muscle tone, and impairment of rotarod performance.
[1]. Dubinsky B, et al. 5-ethoxymethyl-7-fluoro-3-oxo-1,2,3,5-tetrahydrobenzo[4,5]imidazo[1,2a]pyridine-4-N-(2-fluorophenyl)carboxamide (RWJ-51204), a new nonbenzodiazepine anxiolytic. J Pharmacol Exp Ther. 2002 Nov;303(2):777-90.
Kinase experiment: | For each sample, a portion of the membrane fraction containing 0.1 to 0.2 mg of protein is incubated in 2 mL of a 3 mM phosphate-buffered solution containing 0.1 M NaCl and 0.01 to 0.03 μCi of a 3H-labeled ligand [3H]Ro15-4513, [3H]flumazenil. The receptor-ligand binding reaction is allowed to reach equilibrium at an ambient temperature of 21-23°C (30 min) and then the reaction is terminated by vacuum filtration to separate the incubation medium from the biological membranes. The membrane samples are washed to remove unbound ligand. The3H bound to each membrane sample is quantified using liquid scintillation spectrometry. |
Animal experiment: | Adult rats are deprived of water for 48 h and are deprived of food for at least 16 h before testing. After the first 24 h of water deprivation, they are placed in a sound-attenuating chamber for a training period, in which they are allowed 200 licks from a bottle containing tap water. The experiment is performed the next day. Vehicle or compounds are administered orally by gavage, and at specified times after dosing, rats are placed in the chamber and allowed access to tap water. The first lick at the stainless steel sipper tube of a water bottle initiates a 3-min test session in which every 20th lick is punished by a 0.2 s, 0.5 mA shock (root mean square, measured across the electrodes) delivered via the sipper tube. If rats fail to drink within 5 min, the experiment is terminated, and they are evaluated for signs of CNS depression. Rats are not reused in this experiment. The anxiolytic effectiveness of a compound in this assay is determined from the number of rats, at each dose, that receive a number of shocks that is equal to or greater than the calculated 90th percentile of the number of shocks received by approximately 600 vehicle-treated rats. This criterion is eight shocks when rats are tested 1 h after administration and 10 shocks when rats are tested 4 h after administration. |
References: [1]. Dubinsky B, et al. 5-ethoxymethyl-7-fluoro-3-oxo-1,2,3,5-tetrahydrobenzo[4,5]imidazo[1,2a]pyridine-4-N-(2-fluorophenyl)carboxamide (RWJ-51204), a new nonbenzodiazepine anxiolytic. J Pharmacol Exp Ther. 2002 Nov;303(2):777-90. | |
| Cas No. | 205701-85-5 | SDF | |
| Canonical SMILES | O=C(C1=C2N(COCC)C3=CC(F)=CC=C3N2CCC1=O)NC4=CC=CC=C4F | ||
| Formula | C21H19F2N3O3 | M.Wt | 399.39 |
| Solubility | Soluble in DMSO | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 2.5038 mL | 12.5191 mL | 25.0382 mL |
| 5 mM | 500.8 μL | 2.5038 mL | 5.0076 mL |
| 10 mM | 250.4 μL | 1.2519 mL | 2.5038 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 34 reference(s) in Google Scholar.)















